EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications

Zhihui Zhou, Qi Niu, Xiyuan Yu, Chaoyong Yang, Zhi Zhu iD

Chemistry – A European Journal · 2026

DOI: 10.1002/chem.71255 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemistry – A European Journal, 2026. Verfasst von Zhihui Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, Department of Chemical Biology, College of Chemistry and Chemical Engineering, …. Hauptthemen laut MEDLINE: Lysosomes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 178 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) has emerged as a transformative therapeutic strategy, but most existing approaches are restricted to intracellular proteins. Lysosome‐targeting chimeras (LYTACs) expand the scope of TPD by enabling the selective degradation of extracellular and membrane‐associated proteins through the endosomal–lysosomal pathway. This review provides a comprehensive overview of LYTAC technology, focusing on its molecular architecture and mechanism of action. We systematically examine the evolution of LYTACs from two key design dimensions: (1) the diversity of protein‐of‐interest (POI) binders, including antibodies, aptamers, small molecules, peptides, and DNA scaffolds; and (2) the expanding repertoire of lysosomal targeting receptors (LTRs), from classical receptors, cation‐independent mannose‐6‐phosphate receptor (CI‐M6PR) and asialoglycoprotein receptor (ASGPR), to emerging tissue‐restricted, multifunctional, and programmable entry routes. Finally, we discuss strategies to enhance degradation efficiency, pharmacokinetics/pharmacodynamics (PK/PD) profiles, and address key challenges for clinical translation, offering a framework for the rational design of next‐generation LYTAC therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysosomesHumansReceptor, IGF Type 2AnimalsProteolysis

Stichwörter der Autor:innen

endocytosis mechanismlysosome‐targeting chimerasmolecular architecturetargeted protein degradationtherapeutic application

Substanzen

Receptor, IGF Type 2

Autor:innen und Institutionen

  • The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, China.
  • Institute of Molecular Medicine, State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Zhi Zhu

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Zhou, Z., Niu, Q., Yu, X., Yang, C., & Zhu, Z. (2026). Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications. Chemistry – A European Journal. https://doi.org/10.1002/chem.71255

Vancouver

Zhou Z, Niu Q, Yu X, Yang C, Zhu Z. Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications. Chemistry – A European Journal. 2026. doi:10.1002/chem.71255

BibTeX
@article{Zhou2026,
  author = {Zhou, Zhihui and Niu, Qi and Yu, Xiyuan and Yang, Chaoyong and Zhu, Zhi},
  title = {Lysosome‐Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications},
  journal = {Chemistry – A European Journal},
  year = {2026},
  doi = {10.1002/chem.71255}
}
Kostenlos starten →